Treatment of a hip capsular injury in a professional soccer player with platelet-rich plasma and bone marrow aspirate concentrate therapy

Kevin J. Campbell · Robert E. Boykin · Coen A. Wijdicks · J. Erik Giphart · Robert F. LaPrade · Marc J. Philippon

Received: 9 August 2012 / Accepted: 24 September 2012 © Springer-Verlag Berlin Heidelberg 2012

Abstract This report presents a 27-year-old male professional soccer player who developed heterotopic ossification of his hip capsule and gluteus minimus tendon after an arthroscopic hip procedure. After removal of the heterotopic bone, the patient had a symptomatic deficiency of his hip capsule and gluteus minimus tendon. A series of orthobiologic treatments with platelet-rich plasma and bone marrow aspirate concentrate improved the patient’s pain and strength as well as the morphologic appearance of the hip capsule and gluteus minimus tendon on magnetic resonance imaging. A series of motion analyses demonstrated significant improvement in his stance-leg ground reaction force and hip abduction, as well as linear foot velocity at ball strike and maximum hip flexion following ball strike in his kicking leg.

Level of evidence IV.

Keywords Platelet-rich plasma · Bone marrow aspirate concentrate · Hip capsular injury · Gluteus minimus tendon tear · Motion analysis

Introduction

The hip capsule is a fibrous and highly vascular soft tissue stabilizer of the joint [2]. Injury to the capsule occurs infrequently but may be associated with traumatic dislocations of the hip in addition to iatrogenic injury during hip arthroscopy or total hip arthroplasty [11, 15, 20, 23]. Capsular deficiency may result in hip instability and/or pain. Classically, hip capsule tears are treated with surgical repair; however, there may be a role for less invasive therapies in select patients with certain occult hip capsular injuries. Recently, orthobiologics have shown promise in the treatment of musculoskeletal soft tissue injuries and may have the potential to treat soft tissue injuries around the hip [14, 18, 22, 24, 25, 27, 28]. Bone marrow aspiration concentrate (BMAC) and platelet-rich plasma (PRP) are two such therapies.

Bone marrow aspirate concentrate contains mesenchymal stem cells which have anti-inflammatory, anti-apoptotic and multipotent capabilities [6, 21]. They have the potential to differentiate into several cell lineages including tenocytes and chondrocytes in the appropriate hematopoietic-inducing microenvironment [6, 7, 19, 32]. Platelet-rich plasma contains a high concentration of platelets, growth factors and cytokines necessary for cell differentiation and tissue healing [9, 29]. Independent use of these biologic therapies has been reported to result in improvement in the mechanical properties and histologic appearance of some musculoskeletal tissues [1, 4, 5, 8, 14, 16, 25–28].

Case report

A 27-year-old male professional soccer player with a preference for kicking with his left leg developed heterotopic ossification of his right hip capsule and gluteus minimus tendon after an arthroscopic hip procedure. The heterotopic ossification was active on a bone scan and classified as Brooker stage II. Subsequently, the patient...
underwent a combination of arthroscopic and open excision of the heterotopic ossification, a lysis of adhesions and capsular closure of the right hip. The heterotopic ossification was located in the anterior and anterolateral hip capsule and the gluteus minimus tendon (Fig. 1). He was placed on 6 weeks of indomethacin post-operatively for heterotopic ossification prophylaxis.

The patient was progressing well with his rehabilitation until 3 months after his procedure when he developed recurrent right hip pain after a cross kick during a scrimmage. A motion analysis evaluation was undertaken to analyse the mechanics of his limb during a kicking motion which demonstrated the apprehension of weight acceptance of the involved limb and significantly decreased the kicking performance. An MRI demonstrated a tear of the gluteus minimus tendon and a defect in the anterolateral hip capsule. It was believed that a revision arthroscopy may not be beneficial for the patient to treat his gluteus minimus tendon and capsular deficiencies, especially in the setting of his history of heterotopic ossification, and the patient elected to proceed with biologic injection therapy to aid in the potential healing of his tendon and capsule tears.

In the operative suite, he underwent an examination under anaesthesia, which demonstrated no evidence of macroinstability of the hip. An ultrasound revealed a 3 cm defect in the capsule immediately lateral to the iliopsoas ligament and fluid in the gluteus minimus tendon consistent with tearing. Over the next 16 weeks, he received 3 total PRP and 2 total BMAC injections. Platelet-rich plasma injections were of 10 cc and injected under ultrasound guidance. A total of 60 cc of bone marrow aspirate was obtained by using the OnControl Automated Bone Marrow Harvest System (Vidacare, San Antonio, TX) from the left posterior superior iliac spine region and was prepared and concentrated to 6 cc. The bone marrow aspirate was also injected under ultrasound guidance. Post-injection, he was limited in hyperextension and external rotation to allow his capsule to heal.

His therapy post-injection was gradually increased to include global hip strengthening. Eight weeks after the final injection, he reported no pain. He was able to kick pain free with either leg. On examination, his right hip range of motion was symmetric to his contralateral hip and pain free. He had grade 5/5 strength throughout all major muscle groups with the exception of internal rotation which was grade 4/5. Radiographs demonstrated a well-preserved joint space with a normal femoral head/neck offset, no evidence of pincer impingement and a minor area of mature heterotopic ossification. A repeat MRI showed improvement in the appearance of the capsule and gluteus minimus tendon with increased scarring and fibrosis in the previous defect. The labrum was healed at the site of the repair. He was cleared to return to sport 8 weeks following his final injection and returned to full activities with his team.

**Performance analysis**

A 10-camera infra-red motion capture system (Eagle, Motion Analysis Corp, Santa Clara, CA) with two force plates (Bertec Corporation, Columbus, OH) and using 54 reflective markers recorded the patient completing a cross soccer pass with his preferred leg which was the motion that caused the capsular injury. Multiple trials were recorded at six time points (1, 22, 35, 60, 81 and 114 days) throughout the treatment. Kinematic analysis of the passing motion was completed using Cortex (Motion Analysis Corporation, Santa Rosa, CA) and The MotionMonitor software (Innovative Sports Training, Chicago, IL). Pain during each kick was rated on a scale from 1 to 10. A one-way analysis of variance (ANOVA) was used to determine
Fig. 2 Mean peak ground reaction force of the stance leg and mean linear foot velocity at ball strike of the kicking leg of the six evaluation sessions throughout treatment. Time points for PRP/BMAC injection are displayed on horizontal axis. A significant increase \((p < 0.01)\) in peak GRF and linear foot velocity at ball strike was observed between pre-treatment and 4 months post-treatment. Error bars represent 1 standard deviation.

Fig. 3 a Mean peak hip abduction of the stance leg. A significant increase \((p < 0.05)\) in peak hip abduction was observed between pre-treatment and 4 months post-treatment. Error bars represent 1 standard deviation. b Maximum hip flexion of the kicking leg following ball strike with 54 reflective markers significantly increased between pre-treatment (left) and 4 months post-treatment (right; \(p < 0.05\)).
The statistical significance of the improvements \( p < 0.005; \) SPSS, IBM Corp, Armonk, NY.

The motion analysis results demonstrated continuous improvement in kicking performance while his subjective pain score consistently decreased over the treatment time period. The mean magnitude of the ground reaction force of his stance leg demonstrated a significant increase from 1,385 N ± 115 before therapy, to a maximum of 2,115 N ± 141 at treatment day 81 \( p < 0.01, \text{Fig. } 2 \). Additionally, the mean peak hip abduction angle of his stance leg increased over the treatment period from 9.3° ± 1.1 to 23.6° ± 1.1 \( p < 0.05, \text{Fig. } 3a \). Both these results suggest an increase in confidence and performance of his involved hip to withstand the high impact load of planting his stance leg during the cross kick. His kicking performance also improved as the linear foot velocity of his kicking leg at the time of ball strike significantly increased from 7.9 m/s ± 0.5 to a maximum of 11.9 m/s ± 1.1 over the same time period \( p < 0.01, \text{Fig. } 2 \). And finally, maximum hip flexion after ball strike in his kicking limb significantly increased over the treatment period \( p < 0.05, \text{Fig. } 3b \).

Discussion

The most important finding of the present study is that a professional soccer player with a hip capsular soft tissue injury experienced improvement in pain, range of motion and strength in his affected extremity with the combination use of PRP and BMC injections. In addition, he demonstrated marked improvement in the kinematic and kinetic performance measures of a cross soccer pass, and his torn hip capsule and gluteus minimus tendon on MRI appeared more morphologically similar to native low-signal tendon tissue.

It is theorized that the proliferation and differentiation of the mesenchymal stem cells contained in BMC into functional tenocytes as compared to either biologic agent used in isolation and may ultimately expedite soft tissue repair in vivo.

The present report provides an example of the combination use of PRP and BMC to seal a hip capsular defect and glueus minimus tendon tear in a high-demand athlete. This case highlights the therapeutic potential that may be derived from the use of PRP and BMC in the treatment of soft tissue injuries of the hip capsule. Although more studies need to be completed to confirm the therapeutic benefits of these agents used in combination, it seems they may offer a plausible alternative to invasive surgical capsule repair in select patients.

Acknowledgments

We would like to thank Kerry Costello, Kelly Newman and Sean Garvey for their contributions to this study.

Conflict of interest

The Steadman-Philippon Research Institute is a 501(c)(3) non-profit institution supported financially by private donations and corporate support from the following entities: Smith & Nephew Endoscopy, Arthrex, Inc., Siemens Medical Solutions USA, Inc., OrthoRehab, Conmed Linvatec, Óssur Americas, Small Bone Innovations, Inc., and Opédix.

References


